Table 1.
Host range analysis of Premi. Quantitative Lysis tests were performed in triplicate. The efficiency of plaquing was calculated by dividing the phage titer on each tested strain by the phage titer on the isolation host.
Sources: 1-Center for phage technology (CPT) Texas A&M University; 2-gift from Subashchandrabose lab at Texas A&M University; 3-from K. Frank, NIH, gift to CPT; 4-from GangaGen, gift to CPT.
| Host organism | Strain | Source | Efficiency of Plaquing | |
|---|---|---|---|---|
| Proteus mirabilis | ATCC 29,906 | Isolation host | 1 | 1.0 |
| Proteus mirabilis | M6, #1 | Clinical isolate | 3 | 2.2 × 10−7± 3.1 × 10−8 |
| Proteus mirabilis | M6, #2 | Clinical isolate | 3 | 2.9 ± 0.3 |
| Proteus mirabilis | M6, #6 | Clinical isolate | 3 | 1.9 ± 0.3 |
| Proteus mirabilis | ATCC 25,933 | Clinical isolate | 1 | 0.0 |
| Proteus mirabilis | ATCC 7002 | Clinical isolate | 1 | 0.0 |
| Proteus mirabilis | ATCC 43,071 | Clinical isolate | 1 | 0.0 |
| Proteus mirabilis | ATCC 35,659 | Quality control strain | 1 | 0.0 |
| Proteus mirabilis | M6, #3 | Clinical isolate | 3 | 0.0 |
| Proteus mirabilis | M6, #4 | Clinical isolate | 3 | 0.0 |
| Proteus mirabilis | M6, #5 | Clinical isolate | 3 | 0.0 |
| Proteus mirabilis | M6, #7 | Clinical isolate | 3 | 0.0 |
| Proteus mirabilis | M6, #8 | Clinical isolate | 3 | 0.0 |
| Proteus mirabilis | M6, #9 | Clinical isolate | 3 | 0.0 |
| Proteus mirabilis | M5, #10 | Clinical isolate | 3 | 0.0 |
| Proteus mirabilis | HI4320 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF10 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF15 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF32 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF44 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF56 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF57 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF64 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF67 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF75 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF78 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF81 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF89 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF99 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | WF113 | UTI isolate | 2 | 0.0 |
| Proteus mirabilis | B446 | Unknown | 4 | 0.0 |
| Acinetobacter baylyi | ADP1 | Unknown | 1 | 0.0 |
| Acinetobacter radioresistens | HM-107 (SK82) | BEI resources | 1 | 0.0 |
| Citrobacter freundii complex | M5, #3 | Unknown | 3 | 0.0 |
| Citrobacter koseri | M5, #2 | Unknown | 3 | 0.0 |
| Enterobacter aerogenes | M6, #3 | Unknown | 3 | 0.0 |
| Enterobacter cloacae complex | M5, #1 | Unknown | 3 | 0.0 |
| Enterobacter cloacae complex | M6, #2 | Unknown | 3 | 0.0 |
| Enterobacter pasteurii | ATCC 23,355 | Unknown | 1 | 0.0 |
| Enterococcus faecalis | ATCC 29,212 | Clinical isolate | 1 | 0.0 |
| Enterococcus faecium | HM-204 (TX1330) | BEI resources | 1 | 0.0 |
| Escherichia coli | ATCC 25,922 | Clinical isolate | 1 | 0.0 |
| Klebsiella pneumoniae | KPC 27 E3(r) 1 | ST258 cps 2 derivative | 1 | 0.0 |
| Klebsiella pneumoniae | KPC 27 D2(r) 1 | ST258 cps 2 derivative | 1 | 0.0 |
| Klebsiella pneumoniae | KPC 27 Soft (r) 1 | ST258 cps 2 derivative | 1 | 0.0 |
| Klebsiella pneumoniae | 1760c Pharr/JR(r) | 1760c derivative | 1 | 0.0 |
| Klebsiella quasipneumoniae | ATCC 700,603 | Clinical isolate | 1 | 0.0 |
| Morganella morganii | M5, #1 | Unknown | 3 | 0.0 |
| Morganella morganii | M5, #2 | Unknown | 3 | 0.0 |
| Morganella morganii | M5, #3 | Unknown | 3 | 0.0 |
| Plesiomonas shigelloides | M5, #4 | Unknown | 3 | 0.0 |
| Pseudomonas aeruginosa | PAO1 | Lab stock | 1 | 0.0 |
| Pseudomonas aeruginosa | ATCC 27,853 | Clinical isolate | 1 | 0.0 |
| Serratia marcescens | M5, #2 | Unknown | 3 | 0.0 |
| Serratia ureilytica | M5, #3 | Unknown | 3 | 0.0 |
| Staphylococcus aureus | ATCC 29,213 | Clinical isolate | 1 | 0.0 |